Davide Carlesimo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Davide Carlesimo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Di Caro
Dermatology Unit, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome
1 shared publication Annunziata Dattola
Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, La Sapienza University of Rome, Italy
1 shared publicationAntonio Giovanni Richetta
Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, La Sapienza University of Rome, Italy
1 shared publicationElena Zappia
Department of Medical Sciences, University of Turin; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy
1 shared publicationGiovanni Pellacani
Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, La Sapienza University of Rome, Italy
1 shared publication- Marco Virone
Dermatology Unit, Department of Medical and Cardiovascular Sciences “Sapienza” University of Rome Rome Italy
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 18 (2)
Hidradenitis suppurativa: state-of-the-art review and update
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels in areas such as the axillae, groin, and inframammary regions. It typically emerges in early adulthood, with a global prevalence of approximately 1%, though regional variations exist. HS significantly affects patients’ quality of life and imposes considerable socioeconomic burdens. It is frequently associated with metabolic syndrome, inflammatory arthritis, and inflammatory bowel disease, reflecting its underlying systemic inflammatory nature. The pathogenesis of HS involves innate immune mechanisms, including macrophages, neutrophils, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and granulocyte colony-stimulating factor, alongside adaptive immune responses mediated by T cells (IL-17, interferon [IFN]-γ) and B cells, which contribute to autoantibody formation and tertiary lymphoid structures. Chronic inflammation results in irreversible tissue damage, tunnel formation, and severe scarring. Treatment strategies vary based on disease severity. Early inflammatory stages benefit from pharmacological therapies, while later stages require a combination of medical and surgical interventions, with surgery often necessary for advanced cases. The introduction of targeted biologic therapies, including TNF-α (adalimumab) and IL-17 inhibitors (secukinumab, bimekizumab), has expanded treatment options beyond traditional antibiotic regimens. Effective management focuses on early intervention to prevent irreversible damage, control symptoms such as pain, and address systemic comorbidities. A timely diagnosis, along with a multidisciplinary and personalized approach, is essential for improving patient outcomes and quality of life.
- 27 August 2025
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 18 (2)
Open AccessHidradenitis suppurativa: state-of-the-art review and update
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels in areas such as the axillae, groin, and inframammary regions. It typically emerges in early adulthood, with a global prevalence of approximately 1%, though regional variations exist. HS significantly affects patients’ quality of life and imposes considerable socioeconomic burdens. It is frequently associated with metabolic syndrome, inflammatory arthritis, and inflammatory bowel disease, reflecting its underlying systemic inflammatory nature. The pathogenesis of HS involves innate immune mechanisms, including macrophages, neutrophils, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and granulocyte colony-stimulating factor, alongside adaptive immune responses mediated by T cells (IL-17, interferon [IFN]-γ) and B cells, which contribute to autoantibody formation and tertiary lymphoid structures. Chronic inflammation results in irreversible tissue damage, tunnel formation, and severe scarring. Treatment strategies vary based on disease severity. Early inflammatory stages benefit from pharmacological therapies, while later stages require a combination of medical and surgical interventions, with surgery often necessary for advanced cases. The introduction of targeted biologic therapies, including TNF-α (adalimumab) and IL-17 inhibitors (secukinumab, bimekizumab), has expanded treatment options beyond traditional antibiotic regimens. Effective management focuses on early intervention to prevent irreversible damage, control symptoms such as pain, and address systemic comorbidities. A timely diagnosis, along with a multidisciplinary and personalized approach, is essential for improving patient outcomes and quality of life.